Nicolas Ketterer
Updated recommendations for diagnosis and treatment of plasma cell myeloma in Switzerland
Samaras P, Zander T, Taverna C, Schmidt A, Pabst T, Mey U, Matthes T, Lerch E, Ketterer N, Heim D, Duchosal M, Driessen C, Betticher D, Bargetzi M, Renner C. Updated recommendations for diagnosis and treatment of plasma cell myeloma in Switzerland. Swiss Med Wkly 2019; 149:w20031.
03.04.2019Updated recommendations for diagnosis and treatment of plasma cell myeloma in Switzerland
03.04.2019Swiss Med Wkly 2019; 149:w20031
Samaras Panagiotis, Zander Thilo, Taverna Christian, Schmidt Adrian, Pabst Thomas, Mey Ulrich, Matthes Thomas, Lerch Erika, Ketterer Nicolas, Heim Dominik, Duchosal Michel A, Driessen Christoph, Betticher Daniel C, Bargetzi Mario, Renner Christoph
Current status and updated recommendations for diagnosis and treatment of plasma cell myeloma in Switzerland
Samaras P, Zander T, Taverna C, Pabst T, Mey U, Matthes T, Lerch E, Ketterer N, Hess U, Heim D, Duchosal M, Betticher D, Bargetzi M, Renner C. Current status and updated recommendations for diagnosis and treatment of plasma cell myeloma in Switzerland. Swiss Med Wkly 2015; 145:w14100.
21.02.2015Current status and updated recommendations for diagnosis and treatment of plasma cell myeloma in Switzerland
21.02.2015Swiss Med Wkly 2015; 145:w14100
Samaras Panagiotis, Zander Thilo, Taverna Christian, Pabst Thomas, Mey Ulrich, Matthes Thomas, Lerch Erika, Ketterer Nicolas, Hess Urs, Heim Dominik, Duchosal Michel A, Betticher Daniel C, Bargetzi Mario, Renner Christoph
A multicenter phase II trial (SAKK 36/06) of single-agent everolimus (RAD001) in patients with relapsed or refractory mantle cell lymphoma
Renner C, Lohri A, Gyan E, Biaggi C, Cogliatti S, Bertoni F, Ghielmini M, Brauchli P, Ketterer N, Bouabdallah K, Trojan A, Zinzani P, Gressin R, Klingbiel D, Dietrich P, Hitz F, Bargetzi M, Mingrone W, Martinelli G, Swiss SAKK and French GOELAMS group from European Mantle Cell Lymphoma Network. A multicenter phase II trial (SAKK 36/06) of single-agent everolimus (RAD001) in patients with relapsed or refractory mantle cell lymphoma. Haematologica 2012; 97:1085-91.
07.02.2012A multicenter phase II trial (SAKK 36/06) of single-agent everolimus (RAD001) in patients with relapsed or refractory mantle cell lymphoma
07.02.2012Haematologica 2012; 97:1085-91
Renner Christoph, Lohri Andreas, Gyan Emmanuel, Biaggi Christine, Cogliatti Sergio B., Bertoni Francesco, Ghielmini Michele, Brauchli Peter, Ketterer Nicolas, Bouabdallah Krimo, Trojan Andreas, Zinzani Pier Luigi, Gressin Rémy, Klingbiel Dirk, Dietrich Pierre-Yves, Hitz Felicitas, Bargetzi Mario, Mingrone Walter, Martinelli Giovanni, Swiss SAKK and French GOELAMS group from European Mantle Cell Lymphoma Network
Current multiple myeloma treatment strategies with novel agents: a European perspective
Ludwig H, Ketterer N, Kropff M, Mendeleeva L, Morgan G, Palumbo A, Plesner T, San Miguel J, Shpilberg O, Sondergeld P, Sonneveld P, Hess U, Harousseau J, Beksac M, Bladé J, Boccadoro M, Cavenagh J, Cavo M, Dimopoulos M, Drach J, Einsele H, Facon T, Goldschmidt H, Zweegman S. Current multiple myeloma treatment strategies with novel agents: a European perspective. Oncologist 2010; 15:6-25.
19.01.2010Current multiple myeloma treatment strategies with novel agents: a European perspective
19.01.2010Oncologist 2010; 15:6-25
Ludwig Heinz, Ketterer Nicolas, Kropff Martin, Mendeleeva Larisa, Morgan Gareth, Palumbo Antonio, Plesner Torben, San Miguel Jesús, Shpilberg Ofer, Sondergeld Pia, Sonneveld Pieter, Hess Urs, Harousseau Jean-Luc, Beksac Meral, Bladé Joan, Boccadoro Mario, Cavenagh Jamie, Cavo Michele, Dimopoulos Meletios, Drach Johannes, Einsele Hermann, Facon Thierry, Goldschmidt Hartmut, Zweegman Sonja
Effect of single-agent rituximab given at the standard schedule or as prolonged treatment in patients with mantle cell lymphoma: a study of the Swiss Group for Clinical Cancer Research (SAKK)
Ghielmini M, Cerny T, Bargetzi M, Ketterer N, Stahel R, Pichert G, Schefer H, Betticher D, Fey M, Waltzer U, Bertoni F, Cogliatti S, Schmitz S, Swiss Group for Clinical Cancer Research. Effect of single-agent rituximab given at the standard schedule or as prolonged treatment in patients with mantle cell lymphoma: a study of the Swiss Group for Clinical Cancer Research (SAKK). Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005; 23:705-11.
01.02.2005Effect of single-agent rituximab given at the standard schedule or as prolonged treatment in patients with mantle cell lymphoma: a study of the Swiss Group for Clinical Cancer Research (SAKK)
01.02.2005Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005; 23:705-11
Ghielmini Michele, Cerny Thomas, Bargetzi Mario, Ketterer Nicolas, Stahel Rolf, Pichert Gabriella, Schefer Hubert, Betticher Daniel C, Fey Martin F, Waltzer Ursula, Bertoni Francesco, Cogliatti Sergio, Schmitz Shu-Fang Hsu, Swiss Group for Clinical Cancer Research
HIV-testing and newly-diagnosed malignant lymphomas. The SAKK 96/90 registration study
D'Addario G, Ketterer N, Fey M, Cavalli F, Lohri A, Egli F, Stahel R, Maibach R, Torhorst J, Dieterle A, Cerny T. HIV-testing and newly-diagnosed malignant lymphomas. The SAKK 96/90 registration study. Leukemia & lymphoma 2003; 44:133-8.
01.01.2003HIV-testing and newly-diagnosed malignant lymphomas. The SAKK 96/90 registration study
01.01.2003Leukemia & lymphoma 2003; 44:133-8
D'Addario Giannicola, Ketterer Nicolas, Fey Martin, Cavalli Franco, Lohri Andreas, Egli Fritz, Stahel Rolf, Maibach Rudolf, Torhorst Joachim, Dieterle Alexander, Cerny Thomas